New Group Should Drive Significant Sample Volume

MILTON, GA, June 04, 2018 (GLOBE NEWSWIRE) -- Attis Industries,Inc. (NASDAQ:ATIS) (the“Company” or “Attis”),an integrated technology and innovations holding company, today announced that it has entered into a partnership with a large healthcare sales representative network with connections in multiple states across the United States (“the Rep Group”).  

The Rep Group includes approximately 300 representatives from across the country, and it will provide toxicology and blood samples for testing in the new Attis federal lab as well as other partner labs that Attis works with throughout the U.S.  Attis Healthcare is continuing to build multi-faceted processing labs across the country to handle the volume of samples driven by its technology driven healthcare solutions model.  The Rep Group began sending in samples to Attis partner labs in May and will continue to ramp up other accounts in those labs, as well as the Attis federal lab in June and throughout the summer through its connections with as many as 3,000 physicians nationwide.  Attis expects to fully realize the benefit of its partnership with the Rep Group by the beginning of September.  “We’re looking forward to an excellent partnership with this group and its network over the coming months and years.  It is exciting to work with high quality individuals in the healthcare space, and we know that this partnership will lead to improved healthcare options for physicians and patients throughout the country,” said Jeff Cosman, Chief Executive Officer of Attis Industries.

The addition of the Rep Group will bolster the Company’s expanding healthcare business, which already includes the management of rural hospital laboratories and a program to enhance emergency room revenue for community hospitals. The Attis Healthcare business also works with long-term care facilities to implement molecular diagnostic testing to assist those facilities in meeting antibiotic stewardship mandates from the U.S. government, and the Company collaborates with businesses to assist in driving down pharmacy and healthcare costs via pharmacogenetic testing and medication management.  “I’m pleased with the growth and direction of our healthcare business and I’m excited about our future as we continue to provide innovative solutions that improve patient outcomes while driving down healthcare costs,” stated Cosman. “Our direction is clear and focused, and we are building a nationwide network of laboratories to focus on healthcare solutions while at the same time developing long-term growth initiatives in our Attis Innovations division.  Each division is a different line of business with experienced industry experts as part of its management team to execute on our clear mission of growth for our shareholders.  We are building a brand and it is Attis Industries Inc.”

Attis Industries, Inc. 
Attis Industries, Inc. (NASDAQ: ATIS) is a holding company defined by our commitment to servicing our customers with unwavering respect, fairness and care. We are focused on finding and implementing solutions for the resource needs and challenges of our customers with a fundamental objective to seek rewarding solutions through technology and innovation. Our healthcare business centers on creating community-based synergies through collaborations and software solutions. Our innovation business strives to create value from recovered resources. For more information, visit:

Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” “would” or similar words. You should consider these statements carefully because they discuss our plans, targets, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. These statements are subject to certain risks, uncertainties, and assumptions, including, but not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; the ability of the Company to continue to meet the listing requirements of NASDAQ; the ability of the Company to execute on a business plan that permits the technologies and innovations businesses to provide sufficient growth, revenue, liquidity and cash flows for sustaining the Company’s go-forward business, and the risks identified and discussed under the caption “Risk Factors” in the Attis Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission (the “SEC”) on April 16, 2018 and the other documents Attis files with the SEC from time to time. There will be events in the future, however, that Attis is not able to predict accurately or control. Attis’s actual results may differ materially from the expectations that Attis describes in its forward-looking statements. Factors or events that could cause Attis’s actual results to materially differ may emerge from time to time, and it is not possible for Attis to accurately predict all of them. Any forward-looking statement made by Attis in this press release speaks only as of the date on which Attis makes it. Attis undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Media and Investors Contact: 
Hayden IR
(917) 658-7878